Hexarelin and ipamorelin are both GHSR-1a agonists that stimulate GH release from anterior pituitary somatotrophs β but they differ fundamentally in receptor selectivity, GH pulse amplitude, and off-target activity profiles. Understanding these differences determines which compound is appropriate for a given research question. This comparison maps the mechanistic landscape and translates it into practical protocol guidance.
The Shared Mechanism β GHSR-1a Activation
Both hexarelin and ipamorelin bind the growth hormone secretagogue receptor 1a (GHSR-1a) β a constitutively active Gq/11-coupled GPCR expressed in anterior pituitary somatotrophs, hypothalamic arcuate/ventromedial neurons, and peripheral tissues (stomach, heart, adipose). GHSR-1a activation β PLCΞ² β IP3/DAG β intracellular Ca2+ release β GH vesicle exocytosis. Both compounds were developed as synthetic mimics of ghrelin (the endogenous GHSR-1a ligand) with improved stability and GH-stimulating potency.
Why GHSR-1a agonism plus GHRH gives more GH than either alone
GHSR-1a agonists and GHRH act through different intracellular pathways in somatotrophs β Gq/11 (GHSR-1a, Ca2+) vs Gs (GHRH receptor, cAMP). These pathways are synergistic: combining CJC-1295 (GHRH analog) + ipamorelin or hexarelin (GHSR-1a) produces GH pulses substantially greater than either alone. This is the mechanistic basis for the CJC-1295/ipamorelin stack β and explains why hexarelin alone (GHSR-1a only) may be less effective than hexarelin + GHRH analog in maximal GH release protocols.
Head-to-Head Comparison
| Property | Hexarelin | Ipamorelin |
|---|---|---|
| Sequence | His-DTrp-Ala-Trp-DPhe-Lys-NHβ (6 aa) | Aib-His-D-2-Nal-D-Phe-Lys-NHβ (5 aa) |
| GHSR-1a affinity | High β highest intrinsic efficacy of synthetic GHRPs | High β selective, clean GHSR-1a agonism |
| GH pulse amplitude | Highest among all GHRPs at equivalent dose | Moderate β lower than hexarelin, higher than GHRP-6 selective |
| GH pulse duration | ~60-90 min post-SC | ~60-90 min post-SC |
| Cortisol/ACTH elevation | Yes β significant ACTH/cortisol co-activation | No β minimal to none (defining advantage) |
| Prolactin elevation | Yes β moderate | No β ipamorelin’s key selectivity feature |
| CD36 cardiac receptor | Yes β hexarelin binds CD36 β cardioprotection | No β ipamorelin has no CD36 activity |
| Appetite stimulation | Moderate (GHSR-1a in hypothalamus) | Mild (same mechanism, lower activity) |
| Receptor desensitisation | Faster β higher-dose protocols desensitise GHSR-1a more quickly | Slower β selective agonism may reduce desensitisation rate |
| Half-life (SC) | ~2 hr | ~2 hr |
| Best research use | Maximum GH pulse, cardiac CD36 research, HPA axis studies | Clean GH secretagogue research, body composition, GH axis without cortisol confounds |
Research Application Guide
Use hexarelin when you need maximum GH pulse amplitude
Hexarelin produces higher peak GH than ipamorelin at equivalent doses due to higher intrinsic GHSR-1a efficacy plus hypothalamic GHRH co-stimulation via arcuate GHSR-1a. For studies measuring maximum GH secretory capacity, dose-response curves, or GH pulse amplitude as the primary variable, hexarelin provides the strongest GHSR-1a-mediated signal. Confound: cortisol and prolactin elevation must be measured and controlled.
Use hexarelin for CD36 cardiac research
Hexarelin is the only synthetic GHRP with documented CD36 binding in cardiac tissue. For research studying the GH-independent cardiac protection mechanism β PI3K/Akt cardioprotection, ischaemia-reperfusion protection, cardiomyocyte survival β hexarelin is irreplaceable. Ipamorelin has no CD36 activity and cannot substitute in cardiac protection protocols.
Use ipamorelin when GH effects must be isolated from HPA axis
Ipamorelin’s defining advantage is GHSR-1a selectivity without cortisol/ACTH/prolactin co-elevation. For body composition studies (where cortisol elevation confounds fat mass and muscle protein synthesis), immune function studies (where cortisol is immunosuppressive), or any study where the clean GH/IGF-1 axis effect is the variable of interest, ipamorelin is the appropriate tool. Running hexarelin and ipamorelin as parallel arms allows isolation of cortisol-dependent vs GH-dependent effects.
Use both in parallel for GHSR-1a selectivity fingerprinting
A single experiment can map the full GHSR-1a selectivity profile: hexarelin vs ipamorelin vs GHRP-6 at equimolar doses. Measure: GH (primary), ACTH, cortisol, prolactin, appetite/food intake, cardiac function markers. This generates a complete selectivity fingerprint across all GHSR-1a-related readouts simultaneously β the most efficient design for characterising GHSR-1a compound selectivity profiles.
Frequently Asked Questions
Why does hexarelin produce more GH than ipamorelin?
Hexarelin has higher intrinsic GHSR-1a efficacy β it activates the receptor more completely per binding event. It also activates hypothalamic GHSR-1a, triggering GHRH co-release from arcuate neurons, which amplifies the pituitary GH response through a second pathway. Ipamorelin activates primarily pituitary GHSR-1a with less hypothalamic amplification.
What is the CD36 cardiac receptor and why does only hexarelin activate it?
CD36 (scavenger receptor class B) is expressed on cardiomyocytes and activates PI3K/Akt cardioprotective signalling when bound by hexarelin. This interaction is independent of GHSR-1a and does not require GH or IGF-1. Ipamorelin was designed for GHSR-1a selectivity and lacks the structural features required for CD36 binding β making hexarelin uniquely suited for cardiac GH-independent protection research.
Can ipamorelin and CJC-1295 replace hexarelin for GH maximisation?
For GH pulse amplitude, CJC-1295 + ipamorelin (GHRH + GHSR-1a dual pathway) typically produces GH pulses comparable to or exceeding hexarelin alone β because GHRH adds a second amplification pathway via cAMP/PKA. However, for CD36 cardiac research and HPA co-activation studies, CJC-1295 + ipamorelin cannot substitute for hexarelin because neither has CD36 activity or significant ACTH/cortisol co-activation.
Which GHRP is best for body composition research?
Ipamorelin is the preferred tool for body composition research because cortisol and prolactin are direct confounds. Cortisol promotes protein catabolism, increases visceral fat deposition, and suppresses anabolic signalling β exactly the variables being studied. Hexarelin’s cortisol co-elevation makes interpreting body composition outcomes mechanistically ambiguous.